ECSP21044672A - Anticuerpos agonistas de flt3 y usos de estos - Google Patents

Anticuerpos agonistas de flt3 y usos de estos

Info

Publication number
ECSP21044672A
ECSP21044672A ECSENADI202144672A ECDI202144672A ECSP21044672A EC SP21044672 A ECSP21044672 A EC SP21044672A EC SENADI202144672 A ECSENADI202144672 A EC SENADI202144672A EC DI202144672 A ECDI202144672 A EC DI202144672A EC SP21044672 A ECSP21044672 A EC SP21044672A
Authority
EC
Ecuador
Prior art keywords
agonist antibodies
flt3
flt3 agonist
antibodies
agonist
Prior art date
Application number
ECSENADI202144672A
Other languages
English (en)
Inventor
Johan Fransson
Phil Gobeil
Dorothea Maetzel
Melissa Beilschmidt
Arif Jetha
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of ECSP21044672A publication Critical patent/ECSP21044672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen anticuerpos agonistas anti-FLT3. Tales anticuerpos agonistas son útiles para la expansión de células dendríticas y el tratamiento contra el cáncer.
ECSENADI202144672A 2018-12-18 2021-06-18 Anticuerpos agonistas de flt3 y usos de estos ECSP21044672A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781213P 2018-12-18 2018-12-18

Publications (1)

Publication Number Publication Date
ECSP21044672A true ECSP21044672A (es) 2021-09-30

Family

ID=71101095

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202144672A ECSP21044672A (es) 2018-12-18 2021-06-18 Anticuerpos agonistas de flt3 y usos de estos

Country Status (21)

Country Link
US (1) US20220025055A1 (es)
EP (1) EP3902836A4 (es)
JP (1) JP2022513961A (es)
KR (1) KR20210111785A (es)
CN (1) CN113544152A (es)
AU (1) AU2019404098A1 (es)
BR (1) BR112021010948A2 (es)
CA (1) CA3120063A1 (es)
CL (1) CL2021001312A1 (es)
CO (1) CO2021007689A2 (es)
CR (1) CR20210327A (es)
DO (1) DOP2021000114A (es)
EA (1) EA202191650A1 (es)
EC (1) ECSP21044672A (es)
IL (1) IL283922A (es)
JO (1) JOP20210151A1 (es)
MA (1) MA54614A (es)
MX (1) MX2021007339A (es)
PE (1) PE20211474A1 (es)
SG (1) SG11202104352XA (es)
WO (1) WO2020128638A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
EP3165236B1 (en) * 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
MY178919A (en) * 2015-03-09 2020-10-23 Agensys Inc Antibody drug conjugates (adc) that bind to flt3 proteins
EP3630841A1 (en) * 2017-06-02 2020-04-08 Pfizer Inc. Antibodies specific for flt3 and their uses
BR112019024604A2 (pt) * 2017-06-02 2020-06-23 Pfizer Inc. Receptores de antígenos quiméricos que alvejam flt3

Also Published As

Publication number Publication date
PE20211474A1 (es) 2021-08-05
DOP2021000114A (es) 2021-09-30
JP2022513961A (ja) 2022-02-09
SG11202104352XA (en) 2021-05-28
CO2021007689A2 (es) 2021-06-21
CL2021001312A1 (es) 2022-01-07
AU2019404098A1 (en) 2021-05-27
WO2020128638A8 (en) 2021-06-03
CR20210327A (es) 2021-09-27
MX2021007339A (es) 2021-07-15
MA54614A (fr) 2022-03-30
IL283922A (en) 2021-07-29
KR20210111785A (ko) 2021-09-13
BR112021010948A2 (pt) 2021-08-31
CN113544152A (zh) 2021-10-22
EP3902836A4 (en) 2022-08-31
JOP20210151A1 (ar) 2023-01-30
WO2020128638A1 (en) 2020-06-25
CA3120063A1 (en) 2020-06-25
US20220025055A1 (en) 2022-01-27
EP3902836A1 (en) 2021-11-03
EA202191650A1 (ru) 2021-10-22

Similar Documents

Publication Publication Date Title
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
ECSP17073743A (es) Moduladores de k-ras
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
DOP2020000040A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
CU20180065A7 (es) Composiciones y métodos para disminuir la expresión de tau
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
NI202000014A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
UY36286A (es) Tratamientos médicos basados en anamorelina
ECSP21044672A (es) Anticuerpos agonistas de flt3 y usos de estos
BR112017008097A2 (pt) método para tratar condições oculares